Logo for Passage Bio Inc

Passage Bio Investor Relations Material

Latest events

Logo for Passage Bio Inc

Study Result

Passage Bio
Logo for Passage Bio

Q4 2023

4 Mar, 2024
Logo for Passage Bio

Study Result

20 Dec, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Passage Bio Inc

Access all reports
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. The Company's lead products in clinical development are TB-403, a novel oligonucleotide modulator of thromboxane receptors (TXRs) and P7C3, a small molecule oral GPCR modulator that targets the vasoactive intestinal peptide (VIP). The company has a bold vision to fulfill the promise of gene therapy by delivering medicines that provide a cure for previously incurable diseases